Restless legs syndrome is not classified as an autoimmune disease. It is officially categorized as a sleep-related movement disorder, defined by an uncomfortable urge to move the legs that worsens during rest and peaks in the evening or at night. However, a growing body of research shows that immune system activity and inflammation play a larger role in RLS than previously thought, which is likely why this question comes up so often.
How RLS Is Currently Classified
The American Academy of Sleep Medicine classifies RLS (also called Willis-Ekbom disease) as a sensorimotor disorder within the sleep medicine field. The two best-established biological drivers are iron deficiency in the brain and changes to the dopamine system. Iron serves as a key ingredient for the enzyme that produces dopamine, so when brain iron levels drop, dopamine signaling goes haywire.
What’s counterintuitive is that RLS doesn’t appear to involve too little dopamine. Postmortem brain studies and spinal fluid analysis show that people with RLS actually have elevated dopamine activity. The current explanation is that low brain iron triggers a compensatory response: the body ramps up dopamine production and release, but the system for recycling dopamine back into neurons becomes impaired. The result is an excess of dopamine floating outside cells, which eventually desensitizes the receptors that respond to it. This creates symptoms that feel like dopamine deficiency even though the raw supply is elevated.
The Immune Connections That Blur the Line
While RLS isn’t autoimmune by definition, research increasingly points to immune dysfunction as a contributing factor. A study of otherwise healthy Danish blood donors found that elevated C-reactive protein (a standard marker of systemic inflammation, measured above 3 mg/L) was associated with RLS. The same study found that high levels of autoantibodies targeting interferon-alpha, a protein the immune system uses to coordinate its response to infections, were also linked to the condition.
A 2024 transcriptome analysis (which maps which genes are actively turned on in a disease) identified nine major biological networks disrupted in RLS. Inflammation and immunology were among the most prominent. The study found very high activity in several immune pathways typically associated with autoimmune and inflammatory diseases: the TNF pathway, toll-like receptor signaling, and a process called Th17 cell differentiation, which is a hallmark of autoimmune conditions like psoriasis and rheumatoid arthritis. Genes in the HLA family, which help the immune system distinguish the body’s own cells from invaders and are strongly implicated in autoimmune diseases, were also dysregulated.
None of this proves RLS is autoimmune. But it suggests the immune system is doing something abnormal in at least a subset of people with the condition, and that “neurological movement disorder” may be an incomplete description of what’s happening biologically.
RLS Shows Up Often Alongside Autoimmune Diseases
One of the strongest indirect links between RLS and autoimmunity is how frequently they occur together. Up to 30% of people with rheumatoid arthritis have RLS, a rate far higher than the roughly 5 to 10% prevalence in the general population. This finding has been replicated across multiple studies over nearly three decades, with recent research reporting prevalence rates of 27 to 31% in RA patients.
RLS also appears at elevated rates in people with multiple sclerosis, celiac disease, and other immune-mediated conditions. The overlap could mean several things: shared genetic susceptibility, chronic inflammation triggering RLS symptoms, or the iron deficiency that often accompanies autoimmune diseases independently causing RLS. Most researchers suspect some combination of all three.
The Gut Bacteria Theory
One of the more intriguing proposed mechanisms connecting RLS to immune dysfunction involves the gut. A study published in Sleep Medicine found that 69% of RLS patients tested positive for small intestinal bacterial overgrowth (SIBO), compared to 28% of general patient controls and just 10% of healthy controls.
Researchers proposed three possible explanations for this striking overlap. First, people with RLS may be genetically predisposed to SIBO due to subtle immune differences. Second, SIBO could trigger the production of autoantibodies that attack nerve tissue in the brain or peripheral nervous system. Third, the chronic low-grade inflammation from SIBO could raise levels of hepcidin, a hormone that restricts iron absorption into the brain, creating exactly the kind of brain iron deficiency known to drive RLS. This last hypothesis is particularly compelling because it connects the immune system to the established iron-dopamine pathway without requiring RLS itself to be autoimmune.
What This Means in Practice
If you have RLS and an autoimmune condition, treating the underlying inflammation may improve your leg symptoms. Some people with celiac disease, for example, see RLS improve after adopting a gluten-free diet, likely because reducing intestinal inflammation restores normal iron absorption. Similarly, addressing SIBO with appropriate treatment has been reported to help some RLS patients, though large clinical trials on this approach are still lacking.
For people with RLS alone, the immune findings don’t yet change standard treatment, which focuses on correcting iron deficiency (typically targeting a ferritin level above 75 ng/mL) and, when needed, medications that modulate dopamine or other neurotransmitters. But the research does suggest that unexplained RLS, especially cases that don’t respond well to iron supplementation or dopamine-related treatment, might benefit from investigating inflammatory or gut-related contributors that a standard workup would miss.
The honest answer is that RLS sits in a gray zone. It is not an autoimmune disease by any current medical definition, but it involves more immune system activity than a pure neurological movement disorder should. The condition likely has multiple subtypes with different underlying drivers, and for some people, immune dysfunction may be a significant piece of the puzzle.